Surgery

Surgery is usually the first treatment used for a brain tumour. The aim of surgery is to remove as much of the tumour as possible, while minimising damage to surrounding healthy brain. Learn more here.

Radiotherapy

X-rays and other forms of radiation can destroy tumour cells or delay tumour growth. Radiotherapy is recommended for all people with high-grade tumours because it can prolong their survival. Learn more here.

Personalised Medicine

Cure Brain Cancer Foundation is strongly supporting research that is building on existing biomarker knowledge and identifying additional markers in brain cancer, to support the development of personalised therapies and diagnoses. Read more here.

Immunotherapy

Immunotherapy is a type of cancer treatment that boosts/trains the body’s natural defences to fight cancer. Immunotherapy helps the immune system fight cancer, as cancer cells have ways to avoid destruction by the immune system. Learn more here.

Chemotherapy

Chemotherapy is the use of drugs to kill cancer cells, usually by stopping the cancer cells’ ability to grow and divide. The goal of chemotherapy can be to destroy cancer cells remaining after surgery, slow a tumour’s growth, or reduce symptoms. Learn more here.

Other Treatments

Other treatments including radiosurgery, the CyberKnife, Gamma Knife and Proton Beam Therapy are all explored in further detail here.

Main Banner

Introduction

Articles Section With Search Block

Disclaimer

Newsletter

Treatments

The treatment options for brain tumour and brain cancer patients are not extensive; a summary of those available is provided here.

Brain Cancer

Facebook

Twitter

Linkedin

Instagram

Donate

Login

Register

Contact Us

02 8973 1400

info@curebraincancer.org.au

ACNC-Registered-Charity-Log

Home

News

Impact

Contact

Causes of Brain Cancer

Primary and Secondary Brain Cancer

Brain Cancer Grades

Facts and Statistics

What is Brain Cancer?

Acoustic Neuroma

Astrocytoma

Brain Stem Glioma

Chordoma 

CNS Lymphoma

Craniopharyngioma

Diffuse Intrinsic Pontine Glioma (DIPG)

Diffuse Midline Glioma

Ependymoma

Glioblastoma (GBM)

Medulloblastoma 

Meningioma

Metastatic Brain Tumours 

Mixed Glioma

Oligodendrogliomas 

Optic Nerve Glioma 

Pineal Tumours 

Pituitary Tumours 

Primitive Neuroectodermal (PNET) 

Rhabdoid Tumour 

Schwannoma

Types of Brain Cancer

Signs and Symptoms

Genetic Testing

Physical Examination

Imaging

Procedures

Getting Diagnosed

About Clinical Trials

Our Research Impact

Take Part in a Clinical Trial

Clinical Trials

For Clinicians

Frequently Asked Questions

{Brain} Cancer

What's Next?

Fertility

Return to Life

Intimacy

After Diagnosis

Donating Tissue and Data

Early Access to Palliative Care

Cost of Treatments and Care

Accessing Treatments and Care

Side Effects of Treatment

Rehab

After Treatment

Legal Health

Psycho-social Health

Physical Health

Financial Health

Living with Brain Cancer

Decision Support

Emotional Support

Involving Your Children

Caring for Someone with Brain Cancer

Support Information

Support > {Information}

Our Research Strategy

2021 Early Career Fellowship: Dr Yolanda Sanguino

2017 Early Career Fellowship: Dr Laura Genovesi

Role of targeting in the management of malignant brain tumours

Breast and Brain Collaborative Grant

Microglia targeting of glioblastoma and establishment of a new glioma imaging model

CNS tumours in children: a potential role for the folate metabolic pathway 

Vascular biomarkers in malignant glioma

Can we find genes that predict which GBM patient will become a long term survivor?

The Involvement of the Kynurenine Pathway in Glioma Pathogenesis

Using the power of the immune system to treat glioblastoma

Proteomic profiling of glioblastoma multiforme: using protein signatures to define patients with a favourable outcome and to identify protein targets for therapeutic intervention

Consequences of loss of ADAM22 in brain tumour formation

New windows into the brainstem and DIPG tumours

Improving the radiosensitivity of diffuse intrinsic pontine gliomas (DIPG) by targeting hypoxia and sugar metabolism 

Brain Cancer Discovery Collaborative

Exploiting chloroquine as an anti-glioma agent

Underexpression of prostaglandin D synthase: a key molecular event in the transition of a low grade astrocytoma to an anaplastic astrocytoma

Cure Brain Cancer Foundation’s 2019 contribution to the DIPG Collaborative

Growth factor mediated suppression of TGF-B signalling enhances brain tumour development

A comprehensive methylation analysis of 1p and 19q: a method to identify putative tumour suppressor genes in gliomas

Mechanisms of initiation and prevention of brain tumours

NICHE HGG Clinical Trial Grant

Using novel approaches to regulate cancer DNA for treatment of brain cancer and in breast cancer spread to the brain

Targeted delivery of hypoxia selective anticancer agents - a new approach for the treatment of glioblastoma multiforme

Pre-clinical evaluation of TRAIL sensitivity in malignant glioma

Developing a new animal model for malignant gliomas

Cure Brain Cancer Foundation’s 2020 contribution to the DIPG Collaborative

Will selective p38 MAPK inhibitor prevent brain tumour progression and metastasis?

Genetic markers of clinical aggressiveness in glioblastoma and anaplastic oligodendroglioma

Brain Cancer Translational Research Officer

Visiting Academic Program at the Lowy Cancer Research Centre

Cure Brain Cancer Foundation’s 2018 contribution to the DIPG Collaborative

Delivering the right drug to the right patient: predictive biomarker discovery

Research We Fund

Validating a blood test for glioma diagnosis and monitoring

Imaging and molecular determinants of response to chemoradiation in glioblastoma

Improving immunotherapy outcomes in brain cancer

A pilot study of nivolumab in paediatric patients with hypermutant cancers

Pilot study to evaluate the role of Tks5 in malignant glioma invasion

Epigenetic defects in glioma: towards a new therapeutic strategy

SEQuential ImmunoTherapy in patients with Underserved Rare cancers (SEQUITUR)

Testing novel drugs and developing novel models of recurrent disease to find a cure for brain cancer

Using mini-brain models for personalised brain cancer care

Cure Brain Cancer Biomarker and Translational Research Lab (Funded in partnership with the Love for Lachie fundraising group)

A brain tumour stem cell resource for glioma research

Cure for Life Chair in Neuro-Oncology Fund

Australasian participation in the international BIOMEDE (Biological Medicine for Diffuse Intrinsic Pontine Glioma Eradication) study 

Uncovering novel drug targets to treat primary brain cancer

Mixing old treatments with new drugs to cure brain cancer

Powering and arming the immune system to combat Glioblastoma

The therapeutic targeting of cell cycle regulators and mechanisms of resistance to cell cycle therapy in Medulloblastoma

Designing Immune Killer Cells for Adults and Children with Brain Cancer

Cure Brain Cancer Foundation’s 2017 contribution to the DIPG Collaborative

Pharmacological inhibition of MCL-1 and BCL-XL to treat human brain cancer

Cure Brain Cancer Foundation’s 2016 contribution to the DIPG Collaborative

Wainwright Laboratory Research as Part of the John Trivett Fellowship for Brain Cancer

New cures for brain cancer, using novel technology for cancer-cell targeted drug discovery

Cure Brain Cancer Head of Biomarker and Translational Research

Zero Childhood Cancer: Children’s Cancer Institute Personalised Medicine Program

VEliparib, Radiotherapy and Temozolomide trial in newly diagnosed Unmethylated MGMT glioblastoma (VERTU)

Plan/ Design/ Master Protocol Development of the international adaptive clinical trial for glioblastoma multiforme

Queensland Brain Tumour Bank

Circulating MicroRNA as a biomarker in brain cancer

Targeting the epidermal growth factor receptor in high grade glioma

Overcoming resistance to antibody-drug conjugates in glioblastoma patients

A phase 1 and biodistribution study of KB004 (an anti-EphA3 antibody) in patients with glioblastoma

Understanding how epigenetic abnormalities lead to brain cancers

Exceptional response to avastin will lead to the identification of pre-selection biomarkers for use in patients diagnosed with GBM

Developing targeted EphA2 based imaging technology for glioblastoma

Pharmacological inhibition of MCL-1 and BCL-XL to treat human medulloblastoma

Novel targeted chemotherapeutic agents against diffuse intrinsic pontine gliomas

Brain Cancer

Support
Information

Research

Get Involved

Brain Cancer

Brain Cancer

Support Information

Research

Get Involved

About Us